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Pertussis is a frequent and significant illness in adults. Be-
cause acellular pertussis vaccines for use in adolescents and
adults have now been developed, it is important to compare
serologic responses in adults after infection with serologic
responses in adults after vaccination. We measured IgG and
IgA antibodies to 4 Bordetella pertussis antigens at∼6-month
intervals for 28 months in 11 adults with pertussis. After
reaching peak levels, titers of antibody to pertussis toxin
decreased more than did titers of antibodies to filamentous
hemagglutinin, pertactin, and fimbriae type 1 and type 2.
Although studies of adults who have been vaccinated with
acellular pertussis vaccines have had shorter follow-up pe-
riods than studies of adults with pertussis infection, the an-
tibody decay patterns are similar in both groups.
In recent years, there has been an increased awareness among
health care professionals of pertussis in adolescents and adults
[1–16]. In fact, the data of Strebel et al. [10] suggest that there
are ∼1 million cases of pertussis in adolescents and adults in
the United States annually. In addition, it is recognized that
the major source of pertussis in infants is infection by adults
with cough illnesses due to Bordetella pertussis infection [3–5,
17–20].
Because B. pertussis illnesses in adolescents and adults are a
significant problem, acellular pertussis vaccines for adults have
been developed and are being evaluated [20–25]. For compar-
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ative purposes, it is important to examine patterns of antibody
decay following vaccination and compare them with patterns
of antibody decay following natural infection. In this report,
we present patterns of antibody decay over a 28-month period
in 11 adults with pertussis and compare these findings with
available data on antibody decay following vaccination.
Methods. Informed consent was obtained from study sub-
jects, and the human experimentation guidelines of the US
Department of Health and Human Services and those of the
trial site in Germany were followed. Adults with culture-proven
and/or serologically proven B. pertussis infection were identified
in households during a large pertussis vaccine efficacy trial
conducted in Germany from 1991 to 1995 [3, 26]. These sub-
jects were asked to provide follow-up serum samples approx-
imately every 6 months for 28 months to monitor their anti-
pertussis antibody values.
IgG and IgA antibodies to 4 B. pertussis antigens (pertussis
toxin [PT], filamentous hemagglutinin [FHA], pertactin
[PRN], and fimbriae type 2 and type 3 [FIM]) were measured
by ELISA using standard techniques, as described elsewhere [3,
4, 12, 13, 15, 16, 27–29]. We used human reference serum from
US Food and Drug Administration lots 3, 4, and 5. ELISA units
were calculated by comparison of the response curve of the test
specimen with that of the human reference serum, with use of
the reference line method.
Results. Data for 11 adults with proven B. pertussis cough
illnesses for whom multiple serum samples were available over
a period of ∼28-months are included in this report. The times
at which serum samples were obtained, in relation to onset of
disease, were as follows: 1 week (range, 0–8 days), 2 months
(range, 0.5–3.5 months), 6 months (range, 5.6–8.2 months),
12 months (range, 9.0–14.3 months), 18 months (range, 15.3–
22.6 months), and 28 months (range, 24.5–35.7 months). Se-
rum samples were not available from all subjects at each time
point. Because serum samples were available from only 3 sub-
jects at the 24-month time point, no data are expressed for this
time point. A minimum of 6 serum samples were required at
each time point for that time point to be included in the study.
The characteristics of the subjects are presented in table 1.
There were 9 women and 2 men, and their age range was 24–
51 years. The median duration of cough was 7 weeks, and 10
(90%) of 11 subjects had paroxysmal cough, 4 (36%) had
whooping, and 4 (36%) had posttussive vomiting. Only 1
woman did not have paroxysms, whooping, or vomiting. None
of the subjects recalled having had a previous illness thought
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1 37, F 27 Nov 1993 5 P, W Culture, serology None None
2 33, F 20 Jan 1994 7 P, W Culture, serology None None
3 40, M 24 Feb 1994 7 P, V Culture, serology None None
4 31, F 25 Mar 1994 12 P, W, V Serology None None
5 27, F 16 May 1994 11 P Serology None 3 doses of DTP
6 24, F 5 Aug 1994 4 P, V Serology None None
7 36, F 10 Sep 1994 7 None Culture, serology None None
8 31, M 9 Oct 1994 8 P, W, V PCR, serology None None
9 24, F 12 Oct 1994 6 P PCR, serology None None
10 34, F 17 Oct 1994 4 P Serology None None
11 51, F 21 Apr 1995 6 P Serology None None
NOTE. DTP, diptheria and tetanus toxoids and pertussis vaccine; P, paroxysmal cough; W, whooping; V, posttussive vomiting.
Table 2. Geometric mean titers (GMTs), as determined by ELISA, of IgG and IgA antibodies to pertussis toxin (PT), filamentous
hemagglutinin (FHA), pertactin (PRN), and fimbriae type 2 and type 3 (FIM) in serum samples obtained from 11 adults with cough






GMT in U/mL (95% CI)
IgG IgA
PT FHA PRN FIM PT FHA PRN FIM
1 week (0–8 d) 6 22 (3–169) 50 (27–94) 28 (5–164) 7 (5–9) 11 (4–28) 11 (4–29) 23 (6–93) 7 (5–10)
2 mo (0.5–3.5 mo) 11 242 (99–592) 243 (117–502) 140 (50–395) 23 (7–76) 30 (12–75) 103 (29–363) 91 (28–290) 10 (5–18)
6 mo (5.6–8.2 mo) 8 104 (40–268) 243 (112–524) 260 (150–449) 12 (4–42) 14 (5–42) 132 (62–279) 62 (26–148) 7 (5–8)
12 mo (9.0–14.3 mo) 10 81 (41–163) 197 (105–369) 216 (137–340) 17 (5–63) 9 (4–25) 134 (66–272) 85 (35–205) 7 (6–10)
18 mo (15.3–22.6 mo) 9 46 (13–156) 116 (60–227) 135 (53–345) 13 (4–42) 9 (4–23) 80 (30–214) 73 (20–266) 7 (5–9)
28 mo (24.5–35.7 mo) 10 45 (18–114) 127 (61–261) 122 (51–288) 16 (4–60) 6 (3–12) 64 (29–143) 66 (20–221) 7 (5–10)
NOTE. D, days; mo, months.
a Time since onset of illness.
to be pertussis, and only 1 subject had received 3 doses of
whole-cell pertussis vaccine in childhood.
The geometric mean titers (GMTs) of specific anti-pertussis
antibodies at the various time points, as determined by ELISA,
are presented in table 2 and figure 1a and 1b . The kinetics
varied substantially by antigen.
Two months after the onset of illness, the GMT of IgG an-
tibodies to PT was 11-fold greater than in the acute-phase
serum samples. It was 5-fold greater at 6 months and 2-fold
greater at 28 months. The GMT of IgG antibodies to FHA
increased 5-fold, and it was still 2.5-fold greater 28 months
after the onset of illness than at the baseline. The GMT of IgG
antibodies to PRN increased 9.3-fold, and it was 4.4-fold greater
than the baseline at 28 months after the onset of illness. The
IgG response to FIM was similar to the response to FHA, but
was less pronounced.
The GMT of IgA antibodies to PT increased 3-fold between
1 week and 2 months, and it had returned to baseline at 1 year.
IgA antibodies to FHA and PRN increased 12-fold and 4-fold,
respectively, and were still 6-fold and 3-fold greater, respectively,
at 28 months after onset of illness than at baseline. The IgA
response to FIM was minimal.
Discussion. The magnitude of IgG and IgA antibody re-
sponses to PT, FHA, and PRN in the 11 subjects in the present
study (median age, 33 years) was greater than that noted in an
earlier study involving 48 subjects in Cleveland aged65 years
[13]. However, the response pattern and slope of decay for
titers of IgG antibody to PT was similar in both studies. This
comparison should be reviewed with some caution, because it
is likely that some of the infections identified in the Cleveland
study were due to other Bordetella species or to other agents
that elicit cross-reacting antibodies to FHA and PRN [12, 13,
16, 26].
The apparent low titer of antibody in response to FIM is
noteworthy. It is attributable to the fact that 6 of the 11 subjects
had no antibody response to FIM. The other 5 subjects had
typical antibody responses to FIM, similar to their antibody
responses to PT, FHA, and PRN. The lack of a response in
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Figure 1. Geometric mean titers (GMTs), as determined by ELISA, of
antibodies to pertussis toxin (PT), filamentous hemagglutinin (FHA), per-
tactin (PRN), and fimbriae type 2 and type 3 (FIM) in serum samples
obtained at selected times after the onset of illness in 11 adults with
pertussis. A, IgG antibody; B, IgA antibody.
these 6 subjects is probably due to the fimbrial serotype of the
infecting organism. In our ELISA, we used a reagent that was
prepared from both fimbriae type 2 and fimbriae type 3 strains.
However, the fimbriae type 3 antigen is weak. Subjects infected
with type 1; 1,3 or untypable organisms would not produce a
measurable antibody response. During the course of this study,
we performed serotyping of 209 B. pertussis isolates, and the
majority (52%) of those isolates were type 1,3; 1 or untypable
strains (S. Ramakrishnan, P. Newland, D. S. L. Xing, U. Hein-
inger, J. D. Cherry, M. J. Corbel, unpublished data).
There have been a number of immunogenicity studies of
acellular pertussis vaccines in adults, but the longest follow-up
periods to date are 1 year (in 2 studies) and 18 months (in 1
study) [20, 24] (T. Le, J. D. Cherry, S.-J. Chang, M. D. Knoll,
M. L. Lee, S. Barenkamp, D. Bernstein, R. Edelman, K. M.
Edwards, D. Greenberg, W. Keitel, J. Treanor, J. I. Ward, un-
published data). Because the ELISA antibody studies were per-
formed in different laboratories and the comparative time
points are imprecise, it is difficult to accurately compare the
decay patterns reported in these studies. However, the rate of
decay of GMTs of antibody to PT following vaccination was
similar for each of 6 different vaccines and was also similar to
the rate of decay of antibody titers following illness that was
noted in our study. Specifically, in these studies, the percentage
decay in GMT of IgG antibody 1 year after vaccination with
the 6 vaccines varied from 52% to 78% (median, 62%–69%),
and, in our study, the decay rate of GMT of IgG antibody 1
year after infection was 66%. In contrast, the titers of IgG
antibody to FHA, PRN, and FIM appear to decay faster fol-
lowing vaccination than following infection. The median decay
rate for GMTs of IgG antibody 1 year after vaccination was
52%, for those immunized with vaccines that contained FHA,
and it was 58%, for those immunized with vaccines that con-
tained PRN. The same rates were 19% and 17% for FHA and
PRN, respectively. The IgG antibody titer decay percentages for
FHA and PRN observed 28 months after infection were similar
to the values observed 1 year after vaccination. These data are
troubling, and they suggest the need for more-prolonged fol-
low-up studies of vaccinated adults. However, these differences
in decay patterns could be due to the timing of when the serum
specimens were obtained. Our first follow-up serum sample
(obtained ∼2 months after onset of illness [range, 0.5–3.5
months]) may have been obtained after peak titers had oc-
curred. Therefore, the decay pattern for IgG antibody to FHA
and PRN may have been artificially flattened.
In the Adult Acellular Pertussis Vaccine Efficacy Trial, decay
patterns for GMTs of both IgG and IgA antibodies to PT, FHA,
and PRN over an 18-month period are available for comparison
(T. Le, J. D. Cherry, S.-J. Chang, M. D. Knoll, M. L. Lee, S.
Barenkamp, D. Bernstein, R. Edelman, K. M. Edwards, D.
Greenberg, W. Keitel, J. Treanor, J. I. Ward, unpublished data).
The 18-month values reported for IgG antibody to PT, FHA,
and PRN are very similar to our findings. However, the values
for IgA antibodies to FHA and PRN were different, with less
decay observed in samples obtained 18 months after illness
than in those obtained 18 months after vaccination.
The finding of persistently high titers of IgA and IgG anti-
bodies to FHA and PRN 28 months after onset of illness, in
conjunction with the absence of similarly high values for an-
tibody to PT, suggests the possibility that the sustained titers
of antibodies to FHA and PRN may be the result of cross-
stimulation caused by other Bordetella species and/or other
infectious agents, as has been noted in other studies [12, 13,
16, 26].
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